Opinion|Videos|October 18, 2024
Challenges in Adopting Novel Therapies
Key Takeaways
- Translating clinical trial results to diverse patient populations is a significant challenge in real-world settings.
- Complex treatment regimens necessitate specialized infrastructure and training for healthcare providers.
Panelists discuss how implementing novel combination therapies or emerging agents from clinical trials into real-world clinical practice for multiple myeloma faces significant challenges, including managing complex dosing regimens, addressing potential toxicities, ensuring patient adherence, navigating insurance coverage and cost issues, and bridging the gap between highly controlled trial conditions and diverse patient populations encountered in everyday clinical settings
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the most significant challenges in implementing novel combination therapies or emerging agents from clinical trials into real-world clinical practice?
Advertisement
Related to this article
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.
Gut microbiome disruption from antianaerobic antibiotics weakens CAR T-cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
What the 2025-2030 Dietary Guidelines Mean for Heart Health
3
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
4
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
5